Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1617]

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple...

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell...

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

$ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory DLBCL$

ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory...

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of...

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend and enhance treatment responses

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend...

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

ASH 2018: Two studies suggest luspatercept reduces need for blood transfusions

Many patients diagnosed with adenomas may not receive colonoscopies in recommended time frame

Many patients diagnosed with adenomas may not receive colonoscopies in recommended time frame

More from ecancer